Skip to main content

Homcy Charles J's Form 4 filing

BridgeBio Pharma, Inc.BBIO · filed Aug 12, 2025

Accession no.
0000950170-25-107510
Filed
Aug 12, 2025
Trade date
Aug 8-11, 2025
Filing delay
4 days
Rule 10b5-1 plan
Checked

This filing lists 3 non-derivative transactions. Open-market sales total $13.9M. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Homcy Charles JCIK 0001192591Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 8, 2025Common StockSSaleDisposed−191,662$45.87F2−$8,791,535.941,025,012Direct
Aug 8, 2025Common StockSSaleDisposed−58,338$46.64F3−$2,720,884.32966,674Direct
Aug 11, 2025Common StockSSaleDisposed−50,000$48.00−$2,400,000916,674Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Represents the weighted average sale price of the shares sold from $45.395 to $46.38 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F3

Represents the weighted average sale price of the shares sold from $46.40 to $46.84 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Remarks

Exhibit 24: Power of Attorney

Read the full filing on SEC EDGAR (opens in a new tab)